From currently available obesity pharmacotherapy, GLP-1 agonist (or combined GLP-1 and GIP agonist) data offer the most promising weight loss, body composition and safety outcomes in older adults; however, more research on muscle/bone mass preservation is needed. The gene discussed is GIP; the disease is obesity due to melanocortin 4 receptor deficiency.